Table 3.
Adjusted Hazard Ratios for the Composite End Point of All-Cause Mortality and Liver-Related Mortality
| All-Cause Mortality, HR (95% CI), P Value | Liver-Related Mortality, HR (95% CI), P Value | |
|---|---|---|
| Age at baseline (per 5-y increase) | 1.36 (1.26–1.47), <.001 | 1.26 (1.06–1.51), .01 |
| HIV transmission route • MSM • Other (male) • Other (female) | 1.0 1.42 (1.01–1.98), .048 0.94 (0.55–1.62), .942 | 1.0 0.91 (0.38–2.18), .837 0.95 (0.27–3.33), .932 |
| Region of origin • European • Other | 1.0 0.66 (0.46–0.95), .024 | 1.0 0.53 (0.21–1.32), .173 |
| ALT (category)a • <3× ULN • ≥3× ULN | 1.0 2.38 (1.48–3.82), <.001 | 1.0 4.00 (1.62–9.89), .003 |
| CD4+ count square root (per unit increase)a | 0.88 (0.86–0.90), <.001 | 0.87 (0.82–0.92), <.001 |
| Use of TAF/TDFa • No • Yes | 1.0 0.47 (0.34–0.64), <.001 | 1.0 0.44 (0.22–0.88), .020 |
| Cumulative ddI/d4T use (per 1-y increase)a | 1.05 (0.98–1.11), .16 | 1.15 (1.02–1.29), .025 |
| Deferral or interruption of antiretroviral therapya • No • Yes | 1.0 1.98 (1.44–2.73), <.001 | 1.0 1.91 (0.57–2.48), .640 |
Adjusted for baseline age, transmission route, region of origin, time-updated CD4+ cell count, time-updated ALT levels, time-updated use of TDF/TAF, time-updated cumulative ddI/d4T use, and ever deferment or interruption of antiretroviral therapy.
Abbreviations: ALT, alanine aminotransferase; CI, confidence interval; d4T, stavudine; ddI, didanosine; HR, hazard ratio; MSM, men who have sex with men; TAF, tenofovir alafenamide; TDF, tenofovir disoproxil fumarate; ULN, upper limit of normal (35 IU/L).
aTime-updated variables.